利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

180 条记录 (耗时 0.056 秒)

    Anti-Viral Effect of an Extract of Ganoderma Lucidum
    54.
    发明申请
    Anti-Viral Effect of an Extract of Ganoderma Lucidum 审中-公开
    灵芝提取物的抗病毒作用

    公开(公告)号：US20080214442A1

    公开(公告)日：2008-09-04

    申请号：US11859729

    申请日：2007-09-21

    申请人： Alice Yu ,  Chi-Huey Wong ,  Jia Tsrong Jan ,  Y.-S. Edmond Cheng

    发明人： Alice Yu ,  Chi-Huey Wong ,  Jia Tsrong Jan ,  Y.-S. Edmond Cheng

    IPC分类号： A61K38/16 ,  C07K14/00 ,  A61P31/12

    CPC分类号： C07K2/00 ,  A61K36/074 ,  A61K38/00

    摘要： Compositions and methods for the treatment viral infections in organisms, particularly flu virus. The methods and compositions of the disclosure involve the administration to mammals and immune cells of a fucose-containing glycoprotein fraction from Reishi. An extract of G. lucidum induces immune responses that are shown to induce increase survivability in mice injected with lethal does of influenza virus. The effect is increased when the G. lucidum extract is dosed prior to injection of the lethal dose of influenza virus.

    摘要翻译： 用于治疗生物体中的病毒感染的组合物和方法，特别是流感病毒。 本公开的方法和组合物涉及向来自Reishi的含岩藻糖的糖蛋白部分的哺乳动物和免疫细胞施用。 灵芝的提取物诱导免疫应答，显示其在注射致死性流感病毒的小鼠中诱导增加的存活能力。 当在注射致死剂量的流感病毒之前配制灵芝提取物时，效果增加。

    Arrays with cleavable linkers
    57.
    发明申请
    Arrays with cleavable linkers 审中-公开

    公开(公告)号：US20070213297A1

    公开(公告)日：2007-09-13

    申请号：US11645188

    申请日：2006-12-22

    申请人： Chi-Huey Wong

    发明人： Chi-Huey Wong

    IPC分类号： A61K31/716 ,  C40B40/12

    CPC分类号： G01N33/54353 ,  A61K31/716 ,  C07H3/06 ,  G01N33/56972 ,  G01N33/56988 ,  G01N33/57415 ,  G01N2400/02 ,  G01N2400/14

    摘要： The invention provides arrays of molecules where the molecules (e.g., glycans) are attached to the arrays by cleavable linkers. The invention also provides methods for using these arrays, methods for identifying the structural elements of molecules bound to these arrays by using the cleavable linkers, especially the structural elements that are important for binding to test samples. The invention further provides methods for evaluating whether test samples and test molecules can bind to distinct glycans on the arrays and useful glycans identified using the methods and arrays provided herein.

    Synthesis of synthons for the manufacture of bioactive compounds
    58.
    发明申请
    Synthesis of synthons for the manufacture of bioactive compounds 审中-公开
    用于生产生物活性化合物的合成子的合成

    公开(公告)号：US20070015260A1

    公开(公告)日：2007-01-18

    申请号：US11481653

    申请日：2006-07-05

    申请人： Chi-Huey Wong ,  Junjie Liu ,  Grace DeSantis ,  Mark Burk

    发明人： Chi-Huey Wong ,  Junjie Liu ,  Grace DeSantis ,  Mark Burk

    IPC分类号： C08B37/00 ,  C12P19/02 ,  C12N9/24

    CPC分类号： C12P19/02 ,  C12N9/88 ,  C12P17/06 ,  C12R1/19

    摘要： The present invention is based on the discovery that 2-deoxyribose-5-phosphate aldolase (DERA, EC 4.1.2.4) and variants thereof can be used to catalyze sequential asymmetric aldol reactions between a wide variety of donor and acceptor aldehydes. The reaction products typically contain at least two new stereogenic centers and can be produced in enantiomerically pure form. As such, DERA catalyzed asymmetric aldol chemistry can be exploited to produce synthons for the synthesis of a variety of bioactive molecules.

    摘要翻译： 本发明基于以下发现：2-脱氧核糖-5-磷酸醛缩酶（DERA，EC 4.1.2.4）及其变体可用于催化多种供体和受体醛之间的顺序不对称醛醇反应。 反应产物通常含有至少两个新的立体中心并且可以以对映体纯的形式制备。 因此，DERA催化的不对称醛醇化学可以被利用来产生用于合成各种生物活性分子的合成物。

    Mannosyl transfer with regeneration of GDP-mannose
    59.
    发明授权
    Mannosyl transfer with regeneration of GDP-mannose 失效

    公开(公告)号：US07018824B2

    公开(公告)日：2006-03-28

    申请号：US11145810

    申请日：2005-06-06

    申请人： Chi-Huey Wong

    发明人： Chi-Huey Wong

    IPC分类号： C12N9/10 ,  C12N15/54 ,  C12N15/70

    CPC分类号： C12N9/1051 ,  C12P19/18 ,  C12P19/32 ,  C12P21/005

    摘要： A one-pot glycosylation reaction is disclosed in which a mannosyl (Man) group is enzymatically transferred to an acceptor molecule. The starting glycoside is a mannosyl 1-phosphate that is enzymatically converted to its GDP derivative via UTP and a pyrophorylase. The formed GDP derivative is used in the enzyme-catalyzed glycosyl transfer. That enzyme-catalyzed glycosyl transfer to an acceptor releases GDP that is enzymatically converted to GTP for further conversion of mannosyl 1-phosphate into its GDP derivative. Also disclosed are a recombinant α1,2-mannosyltransferase that is enzymatically active, is dispersible in an aqueous reaction medium, and free of the transmembrane portion of the native enzyme, as well as DNA encoding that transferase, an expression vector containing exogenous DNA that encodes that enzyme and E. coli cells containing that vector.

    HIV protease inhibitors
    60.
    发明授权
    HIV protease inhibitors 失效
    HIV蛋白酶抑制剂

    公开(公告)号：US06900238B1

    公开(公告)日：2005-05-31

    申请号：US09077712

    申请日：1996-12-09

    申请人： Chi-Huey Wong ,  Deborah H. Slee ,  Karen Laslo

    发明人： Chi-Huey Wong ,  Deborah H. Slee ,  Karen Laslo

    IPC分类号： G01N33/15 ,  A61K31/00 ,  A61K31/40 ,  A61K45/00 ,  A61P31/00 ,  A61P31/18 ,  C07B61/00 ,  C07D207/08 ,  C07D207/16 ,  C12N9/99 ,  C12Q1/02 ,  C12Q1/37 ,  A01N43/36 ,  C07D207/00 ,  C07F9/02

    CPC分类号： C12Q1/37 ,  C07D207/08 ,  C07D207/12 ,  C07D207/16 ,  C07D211/60 ,  C12Q1/18 ,  C40B40/04 ,  G01N2333/16

    摘要： Combinatorial libraries of HIV and FIV protease inhibitors are characterized by α-keto amide or hydroxyethylamine core structures flanked by on one side by substituted pyrrolidines, piperidines, or azasugars and on the other side by phenylalanine, tyrosine, or substituted tyrosines. The libraries are synthesized via a one step coupling reaction. Highly efficacious drug candidates are identified by screening the libraries for binding and inhibitory activity against both HIV and FIV protease. Drug candidates displaying clinically useful activity against both HIV and FIV protease are identified as being potentially resistive against a loss of inhibitory activity due to development of resistant strains of HIV.

    摘要翻译： 艾滋病病毒和FIV蛋白酶抑制剂的组合文库的特征在于α-酮酰胺或羟乙胺核心结构，其侧面为取代的吡咯烷酮，哌啶或氮杂环庚烷，另一侧为苯丙氨酸，酪氨酸或取代的酪氨酸。 文库通过一步偶联反应合成。 通过筛选文库对HIV和FIV蛋白酶的结合和抑制活性来鉴定高效药物候选物。 鉴于HIV和FIV蛋白酶对临床有用的活性的候选药物被鉴定为可能阻止由于HIV的抗性株的发展而导致的抑制活性丧失。